Elan tees up deals as sales of prized drug rise sharply

By Padraic Halpin DUBLIN (Reuters) – Irish drugmaker Elan Corp said it is teeing up a number of deals under a plan to reshape the company through acquisitions and stave off a bid from investment firm Royalty Pharma. Elan, involved in a convoluted takeover saga with Royalty for the past two months, had on Monday rejected a reduced $11.25 per share bid from Royalty, saying it grossly undervalued its prospects. …